Introduction
The actual chemotherapy protocols used in adult acute lymphoblastic leukemia (ALL) treatment, have allowed an increased complete remission rate, 1 although therapyrelated toxicity remains one of the reasons for treatment interruption or discontinuation, which may increase relapse risk. 2 Prediction of toxicity is difficult, because of wide interpatient variation in pharmacokinetics and pharmacodynamics of antileukemic agents and because the same toxicity can be attributable to different drugs.
An important component in ALL maintenance therapy is the antifolate methotrexate (MTX). MTX enters the cells by the reduced folate carrier (RFC) and its action mechanism consists mainly in the competitive inhibition of the dihydrofolate reductase (DHFR) enzyme.
3 DHFR is responsible for the reduction of dihydrofolate (DHF) into tetrahydrofolate (THF). DHF is also generated during deoxythymidylate synthesis, 4 catalyzed by the thymidylate synthase (TS) enzyme which uses as substrates 5,10-methylene-THF and deoxyuridylate. 5,10-methylene-THF is, in turn, the substrate of methylenetetrahydrofolate reductase (MTHFR), a key folate enzyme that generates 5-methyl-THF, necessary for the remethylation of homocysteine into methionine. Thus, MTX-induced inhibition of DHFR results in the depletion of reduced THF forms (including 5,10-methylene-THF), contributing to the inhibition of nucleic acid synthesis and favouring cellular death. 5 Despite its clinical success, MTX can be associated with serious toxicities in a considerable number of patients. There is evidence that toxicity from anticancer drugs can be affected by inherited polymorphisms in genes encoding drug-metabolizing enzymes. Polymorphisms of MTX transporter (i.e. RFC 80G>A), 6 MTX targets (i.e. DHFR 19-bp deletion 7 and TS enhancer 28-bp tandem repeat), 8 and folate-metabolizing enzyme (i.e. MTHFR 677 C>T 9 and 1298 A>C) 10 can affect the effectiveness and the toxic effects of MTX. Recently, the influence of folate polymorphisms in relation with MTXrelated toxicity has been studied mainly in childhood ALL, 2, [11] [12] [13] [14] [15] whilst only a few studies have investigated this relationship in adult haematological patients. 16, 17 In particular, in adult ALL only MTHFR polymorphisms have been investigated and associated with an increased MTXrelated toxicity.
18,19
The aim of our study was to investigate the influence of folate polymorphisms directly involved in the MTX pharmacological pathway in relation with the outcome of adult ALL patients treated with MTX in maintenance therapy. To this purpose we analyzed the effects of the association of polymorphisms in MTHFR, DHFR, RFC and TS genes on therapy-related toxicity and survival.
Design and Methods

Patients
Cases were 122 Italian individuals (all Caucasians) with newly diagnosed ALL according to WHO classification.
20
Patients were recruited from the Unit of Haematology of the University of Ferrara (n=45), Catania (n=17) and Pavia (n=60) in the period between January 2000 and July 2005. ALL cases were persons aged 18-80 years with a mean age at diagnosis of 43.5±18.2 years and 53% of them were male. Of all patients, 83% were B-ALL and 17% were T-ALL. Inclusion criteria were age at least 18 years, absence of other active malignancy or human immunodeficiency virus-1-positive status. Patients were classified in two subgroups on the basis of the cytogenetic abnormality; in particular, chromosome translocations with known adverse prognostic significance as t(9;22), t(4;11) were classified as high cytogenetic risk group, whilst the other karyotypes were considered as standard risk group. Peripheral blood samples for all cases were collected at the date of diagnosis by venipuncture, before any pharmacological treatment. At the moment of blood collection, cases gave written informed consent to participate to the study. The study was approved by local Ethics Committee.
Therapy and toxicity evaluation
Patients were treated according to GIMEMA ALL 0496 21, 22 (for those recruited from Ferrara and Catania hospitals) and Hyper-CVAD 23 (for those recruited from Pavia hospital) protocols which included maintenance therapy with MTX administered weekly at the dosage 15-20 mg/m 2 (respectively for GIMEMA ALL 0496 and Hyper-CVAD) for 2-3 years. Haematological (leukopenia, anaemia, thrombocytopenia), and non-haematological (hepatic and gastrointestinal) toxicity was graded according to WHO criteria (grades 0-4). 24 Toxicity was evaluated by independent clinicians before any genotyping was carried out and before they knew the hypothesis of the study. Therefore, toxicity assessment was made in a blinded fashion with respect to the patient genotypes and according to the following procedure: the highest grade of WHO toxicity (haematological or non-haematological) observed in each patient during the maintenance therapy period.
Genotype analyses
DNA was isolated from peripheral whole blood by using the QIAmp DNA Blood (QIAGEN GmbH, Hilden, Germany). Genotyping for MTHFR and RFC polymorphisms detection was performed using polymerase chain reaction (PCR) followed by restriction-fragment length polymorphism analysis. The genotyping protocols for MTHFR 677C>T and MTHFR 1298A>C polymorphisms were performed according to Gemmati et al. 25 The genotyping protocol for RFC 80G>A was adapted from Chango et al. 6 as follows: initial denaturation step of 3 min at 94°C, 36 cycles of 94°C for 30 sec, 59°C for 30 sec, 72°C for 55 sec, and a final extension step of 72°C for 7 min. The PCR product was digested by CfoI (SigmaAldrich, Milan, Italy). The genotyping protocol for DHFR 19-bp deletion was adapted from Jhonson et al. 7 as follows: initial denaturation step of 4 min at 94°C, 36 cycles of 94°C for 55 sec, 62°C for 55 sec, 72°C for 55 sec, and a final extension step of 72°C for 12 min. The genotyping protocol for TS polymorphism was performed according to Horie et al. 8 PCR products were analyzed by electrophoresis on a 10% polyacrylamide gel and visualized with ethidium bromide. All primers were furnished by Sigma-Genosys (Milan, Italy). All PCR cycles were performed in a Peltier Thermal Cycler apparatus (PTC-200; M. J. Research, Inc., Watertown, MA, USA). DNA digestions, if required, were performed according to suppliers' instructions. Confirmation of genotypes was carried out by regenotyping a random selection of samples for each polymorphism investigated. There were no discrepancies between genotypes determined in duplicate. The possibility of inaccurate genotyping performed on leukemic blast DNA, due to loss of heterozygosity, cannot be excluded, although we did not find any discordance concerning the number of combined MTHFR genotypes observed (i.e 677C>T and 1298A>C) from that expected by linkage disequilibrium (data not shown).
Statistical analysis
In this study, the primary outcome of interest was the development of toxicity in patients receiving homogeneous maintenance therapy with MTX. By univariate analysis, odds ratio (OR) and 95% confidence intervals (95% CI) were used to estimate the risk of developing different grades of toxicity after the therapy for each specific genotype. By multivariate logistic regression analysis, adjusted ORs were calculated, with the dependent variable being the toxicity grades according to WHO criteria. The multivariate model included sex, age, lineage, cytogenetic risk (considered as high or standard risk) and the polymorphisms as covariates and they were checked for possible interaction or confounding effects. If a covariate had an effect by 10% or more, then the covariate was considered a confounder factor and the model was adjusted for them. To evaluate the impact of the polymorphisms on different toxicity grades, we performed two series of analyses: the first compared the presence at any toxicity grade (grades 1-4) versus the absence (grade 0) and the second compared intermediate/high toxicity grades (2-4) versus null/low grades (0-1), to further evaluate if polymorphisms were associated with more severe toxicities. In this way, the patients were subdivided in two different toxicity grade groups and all patients were simultaneously included in the analyses. To analyze if the two treatment protocols were associated to different toxicity, we compared by χ 2 the number of patients who developed toxicity in each treatment protocol, accounting the different genotypes. The secondary outcome of the study was the association between survival or relapse rates, and the genotypes. Overall survival (OS) was calculated as the time from the date of diagnosis to the occurrence of the death or the end of follow-up. Relapse freesurvival (RFS) was calculated as the time from the date of diagnosis to the occurrence of the first relapse. OS and RFS were estimated at 2 years of follow-up by KaplanMeier analysis and differences were assessed by the logrank test. The associated hazard risk (HR) and 95% CI were used to estimate the probability of developing an event in the period of follow-up. HRs were calculated by means of Cox's proportionate hazards modelling. P£0.05 was considered statistically significant. All analyses were performed by Systat V.5.0 (Systat Inc., Evanston, IL, USA) and SPSS Statistical Package (SPSS Inc., Chicago, IL, USA).
Results
Patient's baseline
Patient's characteristics are reported in Table 1 . Clinical data about therapy-related toxicity were available for 94 patients. There was no difference in the number of patients developing each kind of toxicity for the two treatment protocols; thus all patients were analyzed together. Among all patients who developed toxicity (n=56), the prevalence of haematological and non-haematological toxicity was as follows: 28 hepatic toxicity (50%), 12 gastrointestinal toxicity (21%), 40 leukopenia (71%), 23 anaemia (41%), 15 thrombocytopenia (27%). Furthermore, when we considered other measures indicating a low tolerance of the patients respect to the chemotherapy, such as the discontinuation of treatment (performed when the number of white blood cells was lower than 2000/µL), the reduction of MTX dose and the delaying chemotherapy, we did not find significant associations with the genotypes for any polymorphisms (data not shown).
Clinical data about survival were available for 118 patients in relation to OS and for 117 patients in relation to RFS (Table1). After 2 years of follow-up, 47% of all patients were alive. Globally, patients who relapsed were 
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29%. The median time to death or relapse was 22 and 13 months, respectively. The genotypes frequencies were in Hardy-Weinberg equilibrium. The frequency of the folate polymorphisms in T-cell and B-cell ALL patients, analyzed by χ 2 , did not show significant differences between two groups (data not shown).
Analysis of toxicity in association with the folate polymorphisms. Grade 0 versus 1-4 Table 2 shows, for the polymorphisms investigated, the risk evaluation of developing several kinds of toxicity obtained when we compared the presence (WHO grades 1-4) with the absence (WHO grade 0) of toxicity, calculated by multivariate logistic regression models.
MTHFR 677C>T
Hepatic toxicity increased proportionally to the number of 677T alleles presents in the genotype of patients (32% CC, 47% CT and 73% TT). Patients with the TT genotype had a 5.23-fold increased risk to develop hepatic toxicity (p=0.028) when compared with the wild-type genotype (CC). Furthermore, TT patients were associated also with a 6.43-fold increased risk of leukopenia (p=0.019), obtained only by univariate analysis.
MTHFR 1298A>C
Leukopenia was underrepresented among patients carrying the 1298C allele (AC+CC) respect to the patients with wild-type genotype (AA), with a significant risk reduction of 2.63-fold (OR= 0.38; p=0.028). 
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Hepatic toxicity was 2.07-and 4.57-fold increased respectively in patients with heterozygous (WD) and homozygous (DD) genotype compared to the wild-type genotype (WW), indicating a possible additive genedosage effect. In addition, when we considered all the carriers of the deletion allele (WD+DD), a 2.42-fold increased risk was confirmed (p=0.052).
TS 28 bp tandem repeat
Anaemia was significantly associated to patients with the 3R3R genotype (p=0.003), when compared with the wild-type genotype (2R2R), showing 8.48-fold increased risk. Further, considering all the carriers of 3R allele (2R3R+3R3R) respect to 2R2R genotype, the increased risk remained significant (OR 4.50; p=0.025).
RFC 80G>A
No significant association was found between this polymorphism and the toxicities investigated (data not shown).
Combined analysis between MTHFR 677C>T and DHFR 19 bp deletion polymorphisms
As both MTHFR 677C>T and DHFR 19 bp deletion polymorphisms resulted in association with an increase in hepatic toxicity, we evaluated them in combined analysis (Table 3 ). All combination yielded ORs greater than unitvalue, although only combinations with appreciable number of cases reached significance. In fact, when we considered the presence of at least one polymorphic allele for both polymorphisms (i.e. CT/TT-WD/DD subgroup) respect to the double wild-type (CC-WW), the risk of developing hepatic toxicity exceeded those found for each single polymorphism (OR 6.82; p=0.018).
Grades 0-1 versus 2-4
We performed a further analysis of toxicity by comparing the low (WHO grades 0-1) with the intermediate-high (WHO grades 2-4) toxicity grades ( Table 2) .
MTHFR 677C>T
Patients with the TT genotype were associated with an increased risk of gastrointestinal toxicity (OR 12.37; p=0.039), not found in the previous analysis (grade 0 vs 1-4). The risk of hepatic toxicity was confirmed and slightly increased, but not significantly, both in CT (OR 3.97; p= 0.098) and TT (OR 9.60; p=0.064) genotypes by multivariate analysis ( 
MTHFR 1298A>C
Hepatic toxicity was greatly underrepresented among patients carrying the 1298C allele. In particular, no patients with homozygous genotype (CC) were affected by hepatic toxicity. Thus, the 1298 C-carriers had a 4.17-fold risk reduction (OR 0.24, p=0.018) of developing hepatic adverse effects respect to the 1298 AA patients. Similarly, leukopenia was underrepresented among patients carrying the 1298C allele, with a 3.12-fold risk reduction for 1298 C-carriers (OR 0.32, p=0.026) respect to the wild-type genotype.
No significant association was found for the other folate polymorphisms investigated.
Survival analysis and polymorphisms
Kaplan-Meier analysis of OS curves showed significant results for MTHFR 677C>T polymorphism. At 2 years of follow-up, the different OS was evident for TT cases 
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compared to 677C-carriers (Log-rank p=0.005) (Figure 1 ). In fact, at 2 years a similar percentage of 677CC and 677CT patients (55%) were alive, whilst among 677TT cases only 14% were alive, with an associated hazard risk of 2.37 (95% CI 1.46-8.45) for 677TT genotype.
No association was found among the other polymorphisms investigated and OS. We calculated also the relationship between RFS and polymorphisms. For this series of analyses no significant association was found, although for RFC 80G>A polymorphism we observed a reduction of RFS at 2 years of follow-up among 80A-carriers respect to wild-types (Log-rank p=0.235; HR 1.60, 95% CI 0.72-3.55; p=0.251).
Discussion
In this study we evaluated the influence of specific folate polymorphisms directly involved in MTX pharmacological pathway, on toxicity and survival in adult ALL patients. We found that MTHFR 677C>T polymorphism was associated with hepatic toxicity, leukopenia and gastrointestinal toxicity. Specifically, patients harbouring the 677T allele exhibited a substantial 5-6-fold increase in incidence of hepatic toxicity and leukopenia (Table 2 ). In addition, considering comparison between lower and intermediate-high grade gastrointestinal toxicity (Table  2 ), 50% of patients had the TT genotype, attributing to this genotype a 12-fold increased risk. As MTHFR 1298A>C is concerned, we found association with leukopenia and with hepatic toxicity (Table 2 ) but in the opposite direction respect to that reported for MTHFR 677C>T. This might be due to the known linkage disequilibrium existing between 677T and 1298C alleles. In the last years, several studies have investigated the relationship between MTHFR polymorphisms and toxicity during MTX therapy in childhood ALL. 2, 11, 12, 14, 15, 26, 27 Most of these studies did not find significant association between the 677T allele and toxicity; 2,12,14,26,27 one study reported a lower rates of episodes of toxicity among patients carrying 677T allele15 and one study showed that individuals with 677T allele experienced more frequently interruptions in MTX treatment, suggesting that MTHFR 677C>T serves as predictor of toxicity during maintenance chemotherapy.
11 These different results are probably attributable to several factors included MTX-dose, treatment protocol, ethnic background, number of patients analyzed. In line with our findings, a decreased haematological toxicity associated to 1298 AC/CC genotypes has been previously described in childhood ALL treated with high-dose MTX, nevertheless these studies did not find a higher toxicity associated with the 677T allele.
12,27
Differently to what observed in childhood ALL, in adult ALL patients treated with MTX previous studies have shown a correlation between MTHFR 677C>T and the increase of mucositis, hepatic and haematological toxicity, 18, 19 in line with our results. It should be noted that the MTX doses administered to our patients during ALL maintenance therapy are lower than the doses used in childhood ALL. Thus, the polymorphism influence might be more clearly expressed during low-dose MTX regimen explaining partly the different results reported in adult and children ALL. New evidence, observed for the first time in this study, regards the influence of DHFR 19 bp deletion polymorphism on MTX toxicity in adult ALL. The homozygous condition of DHFR 19 bp deleted allele was significantly associated with increased hepatic toxicity. As DHFR and MTHFR are two key-folate enzymes functionally linked (DHFR starts a folate reduction process preceding and favouring the 5,10-methylene-THF formation, the MTHFR substrate) and the MTHFR 677C>T and DHFR 19 bp deletion were both associated with an increase in hepatic toxicity, we investigated them in combined analysis, to evaluate a possible additive effect. We found that the risk was even higher when the two polymorphisms were analyzed in combination (Table 3 ) respect to the risk obtained for each polymorphism. However, in combined analysis the small number of patients carrying certain haplotypes limited the possibility to estimate the role of each specific haplotype. To our knowledge, no study has been reported on the relationship between DHFR 19 bp deletion polymorphism and toxicity in adult ALL, although DHFR gene variants, including the DHFR 19 bp deletion, have been investigated in a previous study performed in childhood ALL, showing a correspondence between worse ALL outcome and specific DHFR genotypes.
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A further considerable result of our study concerns the TS enhancer repeat polymorphism and the higher risk of developing anaemia in patients with the 3R3R genotype. Recently, this polymorphism has been studied only in childhood ALL in relation with toxicity, but no association was found, 2,12,27 although 3R3R genotype was associated with a higher risk of hematological relapse, 28 poorer outcome13 and shorter event-free survival. 29, 30 Finally, no association was identified between the RFC 80G>A polymorphism and the toxicities investigated.
Folate metabolism, crucial for important cellular events such as DNA synthesis and DNA methylation, may be affected by polymorphisms in genes codifying key-folate enzymes. Indeed, it has been reported that MTHFR 677C>T and 1298A>C polymorphisms reduce the activity of MTHFR enzyme 9, 10 leading to an increase of homocysteine levels. Further, the DHFR 19-bp deletion poly- 
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© F e r r a t a S t o r t i F o u n d a t i o n morphism 7 has been associated with the increase of gene expression and homocysteine levels. 31 Globally, considering the role of the polymorphisms investigated and the results obtained in this study, we speculate a possible unbalancing of folate homeostasis to explain the increased toxicity associated to specific genotypes. In particular, about the association of the increased hepatic toxicity in patients with MTHFR 677TT and DHFR 19 bp DD genotypes, we hypothesize an additive impact of MTX therapy and MTHFR-DHFR polymorphisms on the unbalancing of folate cycle, via homocysteine. This consideration is based on the following evidences: first, it has been observed acute elevation in homocysteine levels after MTX administration; [32] [33] [34] second, the MTHFR 677C>T and DHFR 19 bp deletion polymorphisms have been describe to elevate homocysteine; 9,31 third, homocysteine seems to have a role in hepatotoxicity by elevation of liver enzymes. 35, 36 Nevertheless, cellular mechanisms explaining the different genotype effects on the occurrence of toxicity remain still not fully clarified.
A second goal of this study was to investigate the impact of the polymorphisms on survival. MTHFR 677TT carriers resulted as the group of patients with lower OS at 2 years of follow-up ( Figure 1) . A limited number of evidences has been reported on the influence of MTHFR polymorphisms and survival in adults. Our results are in line with those previously reported by Chiusolo et al., showing the association between 677TT variant and a reduced survival among adult ALL patients treated with MTX-based maintenance. 19 Similarly, lower disease-free survival or RFS associated with 677T allele was found in two ALL childhood studies. 26, 37 Our result could be partly explained by the fact that the 677TT patients conserve more 5,10-methylene-THF in the cell than carriers of the other genotypes. This condition may counteract the folate-depletive effect of MTX and it may affect MTXefficacy and survival. The analysis of RFS performed in our study showed no significant associations with polymorphisms, although patients carrying the RFC 80A allele had a lower probability of RFS. Though not significant, our results were in line with those of Laverdiere et al., 38 who have shown that childhood ALL patients carrying the 80A allele, had higher risk for relapse or death during induction and maintenance MTX therapy. These data seems to suggest a role for RFC 80G>A polymorphism and the relapse risk and it should be interesting to confirm and extend them in a larger population. Previous studies reported a different clinical response to treatment protocols for specific ALL subtypes, with relatively unfavourable prognosis for T-lineage ALL. 39 In particular, Kager et al. 40 found a lower ability of T-ALL cells to accumulate methotrexate polyglutamate (an important determinant of the antileukemic effects of MTX) associated with a ALL subtype-specific expression patterns for folate pathway genes. In our study, in order to identify potential differences in relation to histology, we compared, for each polymorphism, the genotype distribution in T-ALL vs B-ALL patients. We did not find significant differences for any polymorphism, also probably due to the low number of T-ALL patients. In this regard, further investigations in larger ALL subtype groups might be interesting to identify a possible role for folate gene polymorphisms.
In conclusion, this is the first study which identifies a significant role of folate polymorphisms, such as DHFR 19 bp deletion and TS 28 bp repeat, in association with MTX-related toxicity and survival in adult ALL patients. Further, it confirms the influence of MTHFR polymorphisms on ALL outcome. Our findings suggest that pharmacogenetics influence MTX therapy-related toxicity in adult ALL enhancing the risk of haematological and nonhaematological toxicity and have an impact on survival. Identification of new genotype/phenotype associations, once translated into routine clinical use, might provide a novel tool to improve tailored therapy taking into account the genetic background of the patient. We are aware of the limit of our study due to the small sample size, thus definitive conclusions should be drawn with extreme caution, and further larger studies are needed to confirm the present findings.
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